GERN
Geron Corp
stockNASDAQ
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.16 | 2026-10-21 | -18.66% | 2.186 |
| 1M | 1.25 | 2026-09-28 | -24.52% | 1.522 |
| 3M | 1.45 | 2026-07-28 | -34.93% | 0.521 |
| 6M | 1.51 | 2026-04-28 | -37.52% | 0.516 |
| 1Y | 1.28 | 2025-10-28 | -26.29% | 1.266 |
| 2Y | 4.22 | 2024-10-28 | -77.64% | — |
| 5Y | 1.57 | 2021-10-28 | -39.90% | 0.278 |
Geron Corp (NASDAQ:GERN) stock price today is $0.94, and today's volume is 45,387,881. GERN is down 17.957% today. The 30 day average volume is 8.38M. GERN market cap is $606.17M with 642.47M shares outstanding.